

# Cancer Incidence Data, Sri Lanka

**2007**

# Cancer Incidence Data: Sri Lanka Year 2007



National Cancer Control Programme  
555, Elvitigala Mawatha  
Colombo 05  
Sri Lanka

*Cancer Incidence Data - 2007*

© National Cancer Control Programme - 2013

9th Publication

**Cancer Surveillance Team**

Dr. Neelamani Paranagama (Director)  
Dr. Eshani Fernando (Deputy Director)  
Dr. Suraj Perera  
Dr. Hemantha Amarasingha  
Dr. Nirmala Jayanthi  
Dr. Kamal Seneviratna  
Dr. Asanga Hemaratne  
Dr. Kamani Ruhunage  
Dr. Samarakoon Pushpika  
Sr. Chamila Peiris

**Contributors**

**Data collection**

Dr. K.G. Nirmala Jayanthi  
Dr. Asanga Hemaratne  
Dr. J.P.N. Rupasingha  
Dr. I.D. Ediriweera  
Dr. W.M.N.P. Kumari  
Dr. R.M.J.K. Rajapaksha  
Dr. H.R.S.G. Bandara

**Data coding and verification**

Dr. Nirmala Jayanthi

**Data entry**

Ms. Shakila Boteju  
Ms. Prabashi Gayanthika

**Analysis**

Statistical analysis and editing was done by Dr. Eshani Fernando, Deputy Director, assisted by Dr. Nirmala Jayanthi

Special thanks to Mr Dilip Hensman of the WHO for the GIS mapping.

**Support staff**

Mr. Saman Kumara Mahalekam  
Ms. Thushari Dhammika  
Mr. U.K. Sumanasiri  
Mr. Siripala Perera

ISSN: 2345 9107

Printed by;  
Gunaratne Offset Ltd.  
Wellampitiya

## **Message from the Minister of Health**



It is a great pleasure to issue a message to the 9th edition of 'Cancer Incidence Data: Sri Lanka' published by the National Cancer Control Programme of Ministry of Health. This publication gives a detailed description of cancer incidence data of year 2007.

Government of Sri Lanka declared the year 2013 as the year of Non Communicable Disease Prevention. Since cancer is a main non communicable disease, information of incidence of cancers is important in planning, implementation & monitoring of cancer control activities island wide. I hope this information will be helpful for all stakeholders in the provision of comprehensive cancer care involved in primary prevention, early detection, diagnosis and treatment, rehabilitation and supportive care. During last few years Ministry of Health has taken several steps to strengthen provision of comprehensive cancer care throughout the country.

I appreciate the hard work of Director and staff of the National Cancer Control Programme and continued support of World Health Organization for this activity.

**Hon Maithripala Sirisena**



## **Message from Deputy Minister of Health**



I am happy to issue a message to the 9th edition of 'Cancer Incidence Data: Sri Lanka' published by the National Cancer Control Programme of Ministry of Health.

Ministry of Health provides comprehensive cancer care through its curative and preventive health institutions free of charge at the point of delivery. Since major portion of cancer care is offered by the Ministry of Health, information on occurrence of cancer in Sri Lanka is important in further strengthening of cancer care in Sri Lanka.

The contribution of Director and staff of the National Cancer Control Programme and other stakeholders for this activity is highly appreciated. .

**Hon. Lalith Dissanayaka**



## **Message from Secretary, Ministry of Health**



It is with pleasure that I send a message for the publication, “Cancer Incidence Data Sri Lanka-2007” which is the 9th publication in the series. According to the published data, cancer incidence is increasing in Sri Lanka.

It is needless to stress upon the importance of data on cancer incidence for planning and implementation of cancer control strategies as well as monitoring the activities of cancer control programmes and evaluating the effectiveness of those programmes in Sri Lanka.

The series of cancer incidence data publications will be very useful for researchers and for epidemiologists to analyse trends related to main cancers in Sri Lanka and this ecological data would be very useful to generate hypothesis for research.

The information provided in this book would also be useful for cadre projections for cancer treatment and control in the country.

Finally, I wish to extend my sincere appreciation to the World Health Organisation for supporting the cancer surveillance activities in Sri Lanka and to the staff of the National Cancer Control Programme for their effort in publishing this document.

**Dr. Y. D. Nihal Jayathilaka**





## **Message from Director General of Health Services**



Publication of incidence data on cancer is a very important task for the control of cancers especially at a time, the Ministry of Health, Sri Lanka has identified control of Non Communicable Diseases as a top priority.

I wish to congratulate the National Cancer Control Programme, for publishing ‘Cancer Incidence Data- 2007’ and thank all those involved in providing the necessary data, collection, analysis and writing of the report. The data presented would be very useful for future planning activities and research.

I wish to place on record my sincere appreciation to the World Health Organisation for the continuous assistance by providing funds for this important activity.

**Dr. P. G. Mahipala**



## **Foreword**



Publication of the cancer registry is an important outcome of Cancer surveillance which is a main strategy in cancer control. The publication of Incidence data for 2007 is followed up annually from the year 2000 which was earlier, done on a five yearly basis. The importance of data in decision making process and in the planning of prevention and control of cancers, is a timely need in the face of an emerging non communicable diseases epidemic.

Researchers, base their work on these facts and figures and more research should be done with the present changes in trends, to overcome this challenge. Our aim is to provide more detailed analysis and most recent data while maintaining the quality and accuracy .

National cancer control programme under the Ministry of Health, has been publishing Cancer Incidence data of all newly registered patients from 1985 onwards and this is the 09th publication. I wish to thank all the previous Directors and staff who contributed in this important task in the past years.

I take pride and pleasure in thanking Deputy Director, Dr Eshani Fernando and the team for making this publication a success Further I wish to offer my sincere gratitude, for the continuous support given to us by the World Health Organization.

**Dr.Neelamani Paranagama**

Director

National Cancer Control Programme

*Cancer Incidence Data - 2007*

## Table of Contents

	Page No.
Cancer surveillance team	ii
Contributors	ii
Message from the Minister of Health	iii
Message from the Deputy Minister of Health	v
Message from the Secretary Health	vii
Message from the Director General of Health Services	ix
Forward	xi
List of tables	xiii
List of figures	xiv
Executive Summary	1
Introduction	2
Methodology	2
Data tables and Graphs	3
List of references	59
Appendix I- Statistical Terminology	60

## List of Tables

Table No.	Description	Page No.
01	General Population: Sex Distribution	3
02	Denominators used for calculation of the Cancer Registry	3
03	Statistics on doctors, hospitals and hospital beds	4
04	Cancer Incidence in Sri Lanka -2007	4
05	Overall Cancer Incidence, 2007 by age and sex	5
06	Leading cancer sites- 2007	6
07	Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites- 2007	7
08	Cancer cases by ethnicity, sex and sub-site, 2007	14
09	Cancer cases by age group-Male 2007	16
10	Cancer cases by age group-Female 2007	18
11	Cancer incidence by sub-site and histological type 2007	20
12	Lip, oral cavity and pharynx	25
13	Lip and anterior part of oral cavity	27
14	Posterior part of oral cavity and pharynx	28
15	Trachea, bronchus and lungs	29
16	Larynx	30
17	Oesophagus	31
18	Stomach	32
19	Colon and rectum	33
20	Colon	34
21	Rectum, anal canal and anus	35
22	Breast	36
23	Cervix uteri	37
24	Ovary	38

<b>Table No.</b>	<b>Description</b>	<b>Page No.</b>
25	Skin	39
26	Brain	40
27	Thyroid gland	41
28	Urinary Bladder	42
29	Hematopoietic and reticuloendothelial system	43
30	Prostate gland	44
31	Basis of diagnosis of cancer patients 2007	46
32	Cancer Treatment 2007	47
33	Cancer Incidence by Geographical area 2007	49

## List of Figures

<b>Figure No.</b>	<b>Description</b>	<b>Page No.</b>
01	General population of Sri Lanka by 5-year age groups- 2007	3
02	Cancer Incidence Rates 2007	4
03	Age Specific Cancer Incidence Rates 2007	5
04	Leading cancer sites 2007	8
05	Leading cancers by age group	9
06	Age specific rates-Lip, oral cavity and pharynx	26
07	Age specific rates-Trachea, bronchus and lungs	29
08	Age specific rates- Larynx	30
09	Age specific rates- Oesophagus	31
10	Age specific rates- Stomach	32
11	Age specific rates- Colon and rectum	33
12	Age specific rates- Colon	34
13	Age specific rates- Rectum, anal canal and anus	35
14	Age specific rates- Breast	36
15	Age specific rates- Cervix uteri	37
16	Age specific rates- Ovary	38
17	Age specific rates- Skin	39
18	Age specific rates- Brain	40
19	Age specific rates- Thyroid gland	41
20	Age specific rates- Urinary bladder	42
21	Age specific rates- Hematopoietic and reticuloendothelial system	43
22	Age specific rates- Prostate gland	44
23	Stage at diagnosis- Cervical cancer	45
24	Stage at diagnosis- Breast cancer	45
25	Stage at diagnosis- oral cancer	45
26	Basis of diagnosis	46
27	Basis of diagnosis by major categories	46
28	Percentage of patients who received different types of treatment	48
29	Cancer Incidence by Districts- 2007	50
30	Male cancer Incidence by Districts 2007	53
31	Female cancer Incidence by Districts 2007	56

## **Executive summary**

A total of 13,635 new cancer cases had been diagnosed in 2007. This number was slightly less than the number recorded in 2006. This observed reduction of new cases was due to the change in the criteria adopted for the inclusion of new cancer cases into the registry. Up until 2007, behaviour codes '1' (uncertain whether benign or malignant borderline malignancy) '2' (carcinoma in situ) and '3' (malignant primary site) were included in the registry. From 2007, a decision was taken to include only the cancers with behaviour code '3' into the registry to be on par with international standards. Out of 13,635 new cases, 6356 were males and 7279, females. New male and female cancer cases in 2006 were 6205 and 7875 respectively. A slight increase in the number of new male cancer cases could be observed from 2006 to 2007 even with the above change in methodology.

In 2007 the overall crude cancer incidence rate (CR) was 68.0 per 100,000 population and the age standardised rate (ASR) was 71.6. The crude incidence rate of cancers in males was 63.8 and in females it was 72.2, showing a female preponderance.

Breast cancer remained the leading cancer in the population in 2007 as well. The CR and the ASR were 9.8 and 9.9 per 100,000 population respectively. These rates were slightly below the rates observed in 2006 (CR and ASR 10.8). This observation could most probably be due to the change in the criteria adopted from 2006 to 2007 in the inclusion of new cases into the registry. The second leading cancer was 'lip, oral cavity and pharynx'. Even though the overall CR and ASR of male cancers have increased from 2006 to 2007 (CR- 62.7 in 2006 to 63.8 in 2007: ASR -69.2 in 2006 to 71.6 in 2007), the crude and age standardised rates of oral cancer among males have remained more or less constant from 2006 to 2007 (CR- 14.4 in 2006 to 14.2 in 2007: ASR 16.0 in 2006 to 15.7 in 2007).

The five leading cancer sites among males were, 'lip, oral cavity and pharynx', 'trachea, bronchus and lungs', oesophagus, 'colon and rectum' and lymphoma. Among females, the top five cancer sites were breast, uterine cervix, thyroid gland, oesophagus, and ovary.

The lifetime risk of developing any type of cancer, (calculated for 0-74 years as the average life expectancy in Sri Lanka in 2007 was 74 years) was one in every 13 people. It was one in every 12 for males and one in every 13 for females.

The treatment modalities recorded for cancer cases diagnosed in 2007 were as follows. Out of all patients, 50% had received radiotherapy, 40% had received surgical treatment, 52% chemotherapy and 14% hormone therapy whereas 1% of the patients had obtained only symptomatic treatment.

Out of all cases, 91.7 percent of the cases had been microscopically confirmed.



## **Introduction**

The National Cancer Control Programme of Sri Lanka which was established in 1980 started publishing cancer incidence data from 1990 presenting the data of 1985 collected from the cancer treatment centres. This annual publication was stopped after publishing data up to 1987. Thereafter the publications were done every 5 years due to logistic issues. Considering the importance of timely dissemination of information, annual publication of cancer incidence data was recommenced from 2006. This publication presents cancer incidence data of 2007. Data on mortality of cancer patients were reported in 2006 based on the cause specific mortality data reported by the Registrar General's Department. As these data were not available until the time of publication, cancer related mortality data of 2007 are not reported in this publication.

## **Methodology**

Cancer incidence data of 2007 was collected from six cancer treatment centres in the country, namely the National Cancer Institute, Maharagama, (NCI, M) and from five other cancer treatment centres situated in Teaching Hospitals Kandy, Karapitiya and Jaffna and General Hospitals Badulla and Anuradapura. (Cancer treatment centres in Batticaloa, Ratnapura and Kurunegala were not functional in 2007; hence data collection was not done.) This was supplemented by oral cancer data sent by the Oral and Maxillo-Facial Surgical Units of Gampaha, Kalutara, Galle and Matale. Patients who had been diagnosed as having cancer microscopically or otherwise were included in the cancer registry in 2007.


Collection of cancer incidence data was done actively by pre-intern medical graduates who had been specifically trained to perform this task by registry staff. Training continued until inter and intra examiner variability in data retrieval was minimal. Patients' clinic record files were used to extract relevant data for the cancer registry. Initially, data retrieval was done under close supervision by registry staff and later, a random sample was checked to improve reliability of data. Data quality checks were made during coding and at the basic analysis level. The clinic record numbers of data sheets with errors were noted and the relevant patient files were re-examined and necessary corrections were done to the data sheets. Data of the Jaffna treatment centre were collected by the centre and sent directly to the registry.

The date of first histological or cytological confirmation or the date of confirmation by clinical investigation was taken as the date of incidence. In instances this information was not available, date of admission to the hospital due to the malignancy was taken as the incidence date.

International Classification of Disease for Oncology (ICD O-3) was used for topographical and morphological coding. This cleaned data was then fed to the computer using CanReg4® package by a data entry operator who had been trained by the registry staff. Duplicate search facility of CanReg4® was utilised to detect duplicate entries. All multiple entries due to patients being registered in more than one treatment centre were identified and removed from the database using the duplicate searching mechanisms in the software by matching basic information of the patient, demographic variables, topography and morphology.

Cases under behaviour code '3' (Malignant primary site) only was included in the analysis by excluding behaviour codes '1' (uncertain whether benign or malignant borderline malignancy) and '2' (carcinoma in situ) to be on par with international standards. Patients in whom cancer had been ruled out and suspected cases whose diagnosis had not been confirmed yet were omitted from the registry.

**Figure 01- General population of Sri Lanka by 5-year age groups -2007**



**Table 01: General Population: Sex Distribution**

Population ('000)	Year						
	2001	2002	2003	2004	2005	2006	2007
Male	9,359	9,350	9,475	9,678	9,782	9,889	9,956
Female	9,438	9,571	9,698	9,757	9,862	9,969	10,083
Sex Ratio <sup>1</sup>	99.2	97.7	97.7	99.2	99.2	99.2	98.7

<sup>1</sup> Number of males per 100 females

Source: Department of Census and Statistics

**Table 02: Denominators used for calculation of the Cancer Registry**

Population ('000)	Year 2007
Male	9,956
Female	10,083
Total	20,039

Source: Department of Census and Statistics

**Table 03: Statistics on doctors, hospitals and hospital beds  
(Government Institutions)**

	Year						
	2000	2001	2002	2003	2005	2006	2007
Doctors (MOO+DSS)	8,600	9,135	10,157	NA	11,152	11,460	12,337
Population per doctor	2,221	2,058	1,863	NA	1,764	1,733	1,625
Hospitals	558	569	576	607	608	614	615
Beds	57,027	57,946	59,144	59,262	61,594	67,024	68,694
Beds per 1000 population	2.9	3.1	3.1	3.1	3.2	3.4	3.4


NA- Not Available

Source: Medical Statistics Unit, Ministry of Health

**Table 04: Cancer Incidence in Sri Lanka- 2007**

Sex	Number	%	CR	ASR
Male	6356	46.6	63.8	70.9
Female	7279	53.4	72.2	72.8
Total	13635	100.0	68.0	71.6


**Figure 2: Cancer Incidence Rates 2007**



**Table 05: Overall Cancer Incidence, 2007 by age and sex**

Age group	Male			Female			Total		
	Cases	Population	Incidence	Cases	Population	Incidence	Cases	Population	Incidence
Not Known	12			9			21		
0-4	118	867	13.6	82	837	9.8	200	1,704	11.7
5-9	58	892	6.5	49	864	5.7	107	1,756	6.1
10-14	58	919	6.3	46	887	5.2	104	1,806	5.8
15-19	59	986	6.0	80	963	8.3	139	1,949	7.1
20-24	82	943	8.7	121	940	12.9	203	1,883	10.8
25-29	102	781	13.1	166	806	20.6	268	1,587	16.9
30-34	117	752	15.6	239	775	30.8	356	1,527	23.3
35-39	159	736	21.6	391	753	51.9	550	1,489	36.9
40-44	297	690	43.0	619	696	88.9	916	1,386	66.1
45-49	522	602	86.7	811	618	131.2	1333	1,220	109.3
50-54	713	534	133.5	1024	551	185.8	1737	1,085	160.1
55-59	908	383	237.1	946	412	229.6	1854	795	233.2
60-64	889	285	311.9	838	303	276.6	1727	588	293.7
65-69	813	222	366.2	761	257	296.1	1574	479	328.6
70-74	720	168	428.6	546	191	285.9	1266	359	352.6
75+	729	196	371.9	551	230	239.6	1280	426	300.5
Total	6356	9,956	63.8	7279	10,083	72.2	13635	20,039	68.0

**Figure 03: Age Specific Cancer Incidence Rates 2007**



**Table 06: Leading cancer sites- 2007**

Rank	Male				Female				Total			
	Site	No.	CR	ASR	Site	No.	CR	ASR	Site	No.	CR	ASR
1	Lip, oral cavity and pharynx	1415	14.2	15.7	Breast	1914	19.0	18.8	Breast	1964	9.8	9.9
2	Trachea, bronchus and lungs	723	7.3	8.3	Cervix uteri	732	7.3	7.4	Lip, oral cavity and pharynx	1813	9.0	9.6
3	Oesophagus	530	5.3	5.9	Thyroid gland	656	6.5	6.1	Cervix uteri	732	7.3	7.4
4	Colon and rectum	409	4.1	4.5	Oesophagus	534	5.3	5.6	Oesophagus	1064	5.3	5.7
5	Lymphoma	363	3.6	3.8	Ovary	529	5.2	5.3	Ovary	529	5.2	5.3
6	Larynx	343	3.4	3.9	Colon and rectum	405	4.0	4.1	Trachea, bronchus and lungs	901	4.5	4.9
7	Leukaemia	332	3.3	3.6	Lip, oral cavity and pharynx	398	3.9	4.0	Colon and rectum	814	4.1	4.3
8	Unknown primary site	326	3.3	3.8	Leukaemia	275	2.7	2.9	Thyroid gland	786	3.9	3.7
9	Prostate gland	305	3.1	3.6	Uterus	263	2.6	2.7	Prostate gland	305	3.1	3.6
10	Stomach	224	2.2	2.5	Lymphoma	257	2.5	2.6	Lymphoma	620	3.1	3.2
	<b>All sites</b>	<b>6356</b>	<b>63.8</b>	<b>70.9</b>	<b>All sites</b>	<b>7279</b>	<b>72.2</b>	<b>72.8</b>	<b>All sites</b>	<b>13635</b>	<b>68.0</b>	<b>71.6</b>

CR: Crude rate per 100,000 population

ASR: Age standardized rate per 100,000 world population

The cumulative incidence rate given in Table 07 is a summary measure of the age specific incidence rates from 1-74 years. It is the summation of values of all the age specific incidence rates multiplied by 5 (as incidence rates were calculated for 5 year age groups) expressed per 100 persons in the population.

The life time risk of developing the leading cancers is also given in Table 07. The life time risk is given as a percentage, the risk of developing a particular cancer per 100 persons in the population as well as risk of developing a particular cancer given as number of persons per new case developed. One in every 12 males and one in every 13 females will develop cancer during their lifetime (0-74 years).



**Table 07: Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years)  
of leading cancer sites- 2007**

ICD O Code	Site	Male		Female		Total	
		Cumulative Rate	Lifetime Risk % <sup>1</sup> (n) <sup>2</sup>	Cumulative Rate	Lifetime Risk % (n)	Cumulative Rate	Lifetime Risk % (n)
C00-C06, C09-C14	Lip, oral cavity and pharynx	1.906	1.888 (53)	0.499	0.498 (201)	1.172	1.165 (86)
C15	Oesophagus	0.761	0.759 (132)	0.714	0.711 (141)	0.737	0.734 (136)
C16	Stomach	0.318	0.318 (314)	0.760	0.760 (132)	0.192	0.192 (521)
C18-C20	Colon and rectum	0.518	0.517 (193)	0.487	0.486 (206)	0.502	0.501 (200)
C32	Larynx	0.536	0.535 (187)	0.030	0.030 (3333)	0.270	0.271 (369)
C33-C34	Trachea, bronchus and lungs	1.113	1.106 (90)	0.232	0.232 (431)	0.651	0.649 (154)
C50	Breast	0.058	0.058 (1724)	2.078	2.056 (49)	1.101	1.095 (91)
C53	Cervix uteri	-	-	0.873	0.870 (115)	-	-
C54-C55	Uterus	-	-	0.326	0.325 (308)	-	-
C56	Ovary	-	-	0.597	0.596 (168)	-	-
C61	Prostate gland	0.473	0.472 (212)	-	-	-	-
C73	Thyroid gland	0.140	0.140 (714)	0.565	0.563 (178)	0.357	0.357 (280)
C80	Unknown primary site	0.465	0.464 (216)	0.247	0.247 (405)	0.349	0.348 (287)
	Lymphoma	0.414	0.414 (242)	0.287	0.287 (348)	0.349	0.348 (287)
	Leukaemia	0.309	0.308 (325)	0.251	0.250 (400)	0.279	0.279 (358)
<b>All sites</b>		<b>8.492</b>	<b>8.141</b> (12)	<b>8.197</b>	<b>7.870</b> (13)	<b>8.311</b>	<b>7.975</b> (13)

1- %- Life time risk as a percentage (per 100 persons)


2- (n)- Number of population per one new case detected

Figure 04: Leading Cancer Sites 2007




**Figure 05: Leading cancers by age group**

**0-14 years  
Male**




**Female**







**15-34 years**  
**Male**




**Female**




**35-49 years  
Male**




**Female**




**50-64 years**  
**Male**



**Female**



**65 years and above  
Male**



**Female**




Table 08: Cancer cases by ethnicity, sex and sub-site, 2007

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Others		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C00 Lip	32	8	28	6	2	2	1				1	
C01 Base of tongue	119	13	113	10	5	2	1					1
C02 Other and unspecified parts of tongue	232	57	206	38	19	14	6	5			1	
C03 Gum	77	40	62	27	13	11	1	1			1	1
C04 Floor of mouth	84	11	71	9	12	2	1					
C05 Palate	88	20	71	14	14	5	2	1			1	
C06 Other and unspecified parts of mouth	360	146	303	88	45	43	11	14			1	1
C07 Parotid gland	28	24	21	18	4	3	2	2	1		1	
C08 Other and unspecified major salivary glands	7	6	5	5	1	1	1					
C09 Tonsil	128	11	118	10	7	1	3					
C10 Oropharynx	56	12	49	8	6	4	1					
C11 Nasopharynx	43	8	36	6	4	1	2	1			1	
C12 Pyriform sinus	134	25	114	18	14	5	5	2			1	
C13 Hypopharynx	31	28	24	15	4	13	2				1	
C14 Other and ill-defined sites in lip, oral cavity and pharynx	31	19	26	12	5	7						
C15 Oesophagus	530	534	433	413	80	99	16	16	1		1	5
C16 Stomach	224	60	179	50	36	6	9	3				1
C17 Small intestine	9	11	8	10		1	1					
C18 Colon	195	177	177	165	9	5	6	7			3	
C19 Rectosigmoid junction	18	23	14	22	1		2	1			1	
C20 Rectum	196	205	163	181	13	18	18	5			2	1
C21 Anus and anal canal	14	15	13	14	1	1						
C22 Liver and intrahepatic bile ducts	112	39	97	33	11	3	3	3			1	
C23 Gallbladder	13	17	11	13	2	3			1			
C24 Other and unspecified parts of the biliary tract	27	24	22	19	4	4	1	1				
C25 Pancreas	33	34	28	27	2	4	3	3				
C26 Other and ill-defined digestive organs	4	2	3	2			1					
C30 Nasal cavity and middle ear	17	7	13	7	2		2					
C31 Accessory sinuses	26	17	19	12	7	3		2				
C32 Larynx	343	29	281	23	46	5	14	1			2	
C33 Trachea	1		1									
C34 Bronchus and lungs	722	178	614	147	58	21	49	10			1	
C37 Thymus	8	4	7	4			1					
C38 Heart, mediastinum and pleura	16	15	15	10	1	2		3				
C40 Bones, joints and articular cartilage of limbs	34	38	26	31	3	2	5	5				
C41 Bones, joints and articular cartilage of other and unspecified sites	12	22	8	19	4	3						
C42 Hematopoietic and reticuloendothelial system	534	460	455	381	43	46	36	28				5
C44 Skin	115	86	96	75	12	4	6	6			1	1
C47 Peripheral nerves and autonomic nervous system	17	15	16	12		1	1	2				

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Others		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C48 Retroperitoneum and peritoneum	13	13	11	12	1	1	1					
C49 Connective, subcutaneous and other soft tissues	55	63	51	54	2	7	1	2			1	
C50 Breast	50	1914	41	1587	5	174	3	146		1	1	6
C51 Vulva		22		16		5		1				
C52 Vagina		24		17		5		2				
C53 Cervix uteri		732		604		97		28		1		2
C54 Corpus uteri		188		165		12		11				
C55 Uterus NOS		75		63		8		4				
C56 Ovary		529		457		41		27				4
C57 Other and unspecified female genital organs		4		3		1						
C58 Placenta		7		6				1				
C60 Penis	54		48		6							
C61 Prostate gland	305		252		31		18				4	
C62 Testis	49		41		7		1					
C63 Other and unspecified male genital organs	1		1									
C64 Kidney	69	37	53	34	5	1	11	2				
C65 Renal pelvis	2	2	2	1		1						
C66 Ureter	2	1	2	1								
C67 Bladder	115	36	93	29	14	4	8	3				
C68 Other and unspecified urinary organs	2	3	1	2		1	1					
C69 Eye and adnexa	25	25	22	24		1	3					
C70 Meninges	2	1	1	1	1							
C71 Brain	164	97	143	89	12	4	9	3				1
C72 Spinal cord, cranial nerves and other parts of the central nervous system	4	6	4	6								
C73 Thyroid gland	130	656	111	597	11	31	8	23				5
C74 Adrenal gland	4	7	3	6	1	1						
C75 Other endocrine glands and related structures	1		1									
C76 Other and dill-defined sites	13	7	12	4		2	1	1				
C77 Lymph nodes	300	199	237	164	42	21	20	14			1	
C80 Unknown primary site	326	191	275	159	32	22	17	9			2	1
<b>Total</b>	<b>6356</b>	<b>7279</b>	<b>5351</b>	<b>6055</b>	<b>660</b>	<b>785</b>	<b>315</b>	<b>399</b>		<b>5</b>	<b>30</b>	<b>35</b>

Table 09: Cancer cases by age group-Male 2007

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00 Lip									1	2	2	10	2	4	5	6	
C01 Base of tongue	1						1	1	3	14	17	9	25	11	11	12	14
C02 Other and unspecified parts of tongue					1		1	2	14	18	30	40	40	28	15	19	24
C03 Gum								1		5	6	8	12	8	9	8	20
C04 Floor of mouth								1	1	4	9	12	19	6	13	10	9
C05 Palate									3	4	11	11	13	14	12	11	9
C06 Other and unspecified parts of mouth								1	3	18	31	30	54	52	63	49	59
C07 Parotid gland				2		1		2	2	1	1	4	6	4	2	2	1
C08 Other and unspecified major salivary glands		1						1	1		1			1	2		
C09 Tonsil					1	1	1		4	6	17	18	33	15	10	10	12
C10 Oropharynx									1	7	11	10	9	8	4	6	
C11 Nasopharynx					1	4	2	2		1	12	1	4	8	1	6	1
C12 Pyriform sinus								1	5	13	14	23	20	18	22	18	
C13 Hypopharynx									2	1	3	6	7	6	3	3	
C14 Other and ill-defined sites in lip, oral cavity and pharynx									1	1	5	4	5	10	2	1	2
C15 Oesophagus	2					1		3	7	24	52	78	71	68	77	79	68
C16 Stomach								1	2	10	26	36	50	35	26	23	15
C17 Small intestine				1	1						2	1	2		1	1	
C18 Colon					1		4	6	6	14	12	36	32	27	27	11	19
C19 Rectosigmoid junction							1		1			1	1	5	4	2	3
C20 Rectum	1					2	3	5	8	7	13	24	32	34	21	15	31
C21 Anus and anal canal											1	2	2	1	2	3	3
C22 Liver and intrahepatic bile ducts		3	1			1			2	2		10	20	21	22	22	8
C23 Gallbladder												3	3	2	2		3
C24 Other and unspecified parts of the biliary tract									1	4	3	6	6	4	1	2	
C25 Pancreas								1	3	7	4	2	4	5	3	4	
C26 Other and ill-defined digestive organs														1		1	2
C30 Nasal cavity and middle ear							1	1		2	2	1	2	3	1	1	3
C31 Accessory sinuses						2				1	2	2	7	6	2	2	2
C32 Larynx							1		9	18	24	36	56	62	56	52	29
C33 Trachea													1				
C34 Bronchus and lungs						2	2	3	9	22	65	88	105	135	119	103	69
C37 Thymus							1	1		1	1	3		1			
C38 Heart, mediastinum and pleura			1		1	1	4	1				1		3	1	3	
C40 Bones, joints and articular cartilage of limbs		1	4	3	13	4	1				2		2	2		2	
C41 Bones, joints and articular cartilage of other and unspecified sites			1		2	1	1			2	1	1		1	1	1	
C42 Hematopoietic and reticuloendothelial systems	7	61	15	28	10	23	21	24	13	30	20	41	54	49	47	47	44
C44 Skin			1		1		1		4	5	5	10	21	15	10	15	27
C47 Peripheral nerves and autonomic nervous system		2	3		1	1		2		3	1	2		2			

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C48 Retroperitoneum and peritoneum					1		1	3		2	2	1	2			1	
C49 Connective, subcutaneous and other soft tissues		4	2			3	3	4	8	3		11	3	4	6		4
C50 Breast									2	2	9	6	7	8	3	4	9
C60 Penis								2	1	2	5	13	8	7	3	7	6
C61 Prostate gland		2						1		1	5	15	29	44	64	65	79
C62 Testis		4	1		1	4	10	10	5	2	4	1	2	2		2	1
C63 Other and unspecified male genital organs					1												
C64 Kidney		7	1	1	1		1		4	2	13	9	4	9	11	4	2
C65 Renal pelvis												1				1	
C66 Ureter												1				1	
C67 Bladder							1		1	1	9	10	12	16	20	17	28
C68 Other and unspecified urinary organs								1			1						
C69 Eye and adnexa		12	4								1	3			1	1	3
C70 Meninges															1		1
C71 Brain		9	12	10	5	6	9	12	11	12	12	11	22	11	6	7	9
C72 Spinal cord, cranial nerves and other parts of the central nervous system		2							1		1						
C73 Thyroid gland				2	3	7	13	10	15	11	10	17	4	13	11	8	6
C74 Adrenal gland		3										1					
C75 Other endocrine glands and related structures		1															
C76 Other and dill-defined sites		2			1		1				1	2	2	1	2	1	
C77 Lymph nodes		4	12	11	12	17	13	14	10	16	22	38	34	25	29	20	23
C80 Unknown primary site	1				1	1	4	2	6	17	24	24	49	71	52	32	42



**Table 10: Cancer cases by age group-Female 2007**

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C00 Lip								1						2	2	1	2
C01 Base of tongue									2	1		1	1	1	2	3	2
C02 Other and unspecified parts of tongue	1						1		3	4	4	13	7	2	6	8	8
C03 Gum							1		1	3	5	5	4	9	5	7	
C04 Floor of mouth	1								1			3	1	1	2	2	
C05 Palate			1					1	1		1	1	2	2	5	1	5
C06 Other and unspecified parts of mouth							1	1	8	2	14	19	16	31	23	31	
C07 Parotid gland						2	1	4	1	1	1	4	4	2	2		2
C08 Other and unspecified major salivary glands								1				2		3			
C09 Tonsil							1				1	1	4	1	2		1
C10 Oropharynx											1	2		5	3		1
C11 Nasopharynx				2	1				1	1	1	1				1	
C12 Pyriform sinus									2	2	1	4	3	4	4	4	5
C13 Hypopharynx								2		3		5	3	4	2	5	4
C14 Other and ill-defined sites in lip, oral cavity and pharynx								1		1	3	3	2	1	4	2	2
C15 Oesophagus								2	8	17	37	73	79	83	94	70	71
C16 Stomach					1					5	2	12	9	12	4	8	7
C17 Small intestine				1				1		1		1		3	2	2	
C18 Colon					1	1	1	10	5	12	16	18	31	29	19	19	15
C19 Rectosigmoid junction										1	1	3	5	4	2	4	3
C20 Rectum						3	3	7	7	13	19	37	33	17	26	17	23
C21 Anus and anal canal										2	4	4	2	1		1	1
C22 Liver and intrahepatic bile ducts		2				1		2	1	2	6	5	5	2	8	1	4
C23 Gallbladder						1			1	1	1	6	4	1	1		1
C24 Other and unspecified parts of the biliary tract									1		5	4	4	4	4		2
C25 Pancreas							1	1	1	6	1	3	7	6	6	2	
C26 Other and ill-defined digestive organs												1	1				
C30 Nasal cavity and middle ear							1			1	1	2		2			
C31 Accessory sinuses											1	5		2	4	1	4
C32 Larynx								1	1	2	1	5	7	1	2	3	6
C33 Bronchus and lungs							1	1	6	10	18	16	29	23	32	21	21
C37 Thymus								1				1		1		1	
C38 Heart, mediastinum and pleura		2		4	2	1	1	1	1					1		1	1
C40 Bones, joints and articular cartilage of limbs			3	7	7	4	3	2	2	1	1	1		1	4		2
C41 Bones, joints and articular cartilage of other and unspecified sites		2	2	1	2	3	1		1	1			2	1	3	2	1
C42 Hematopoietic and reticuloendothelial systems	3	41	19	8	10	11	12	14	16	24	41	43	50	40	54	37	37
C44 Skin		3			1		4	5	6	5	9	13	5	9	6	9	11
C47 Peripheral nerves and autonomic nervous system		4	1			1	1	1	1	1	2			2		1	
C48 Retroperitoneum and peritoneum								1	2	1	2	3	2	1	1		

ICD O Code and Site	Age Group																
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
C49 Connective, subcutaneous and other soft tissues				4	4	5	6	3	3	7	4	6	6	5	2	6	2
C50 Breast	2					3	21	54	144	262	299	316	250	234	144	94	91
C51 Vulva										2	2	3	3	4	2	2	4
C52 Vagina									1	1	1	1	2	3	5	5	5
C53 Cervix uteri							1	9	32	53	114	124	112	91	74	66	56
C54 Corpus uteri						1			6	3	17	39	38	33	32	8	11
C55 Uterus NOS									2	8	8	19	16	12	7	1	2
C56 Ovary			3	4	7	14	13	14	27	51	80	72	77	56	53	35	23
C57 Other and unspecified female genital organs								1	1		1					1	
C58 Placenta						2	2	1	2								
C64 Kidney		7	2			1		3		2	2	6	2	3	3	5	1
C65 Renal pelvis															1		1
C66 Ureter																	1
C67 Bladder					1		1	1	1	3		1	1	5	9	6	7
C68 Other and unspecified urinary organs													1				2
C69 Eye and adnexa		6	2	3				2	1		1		1	4	1	1	3
C70 Meninges												1					
C71 Brain		6	9	3	5	7	4	5	7	8	6	12	15	4	4		2
C72 Spinal cord, cranial nerves and other parts of the central nervous system				1			1	1			1		2				
C73 Thyroid gland	2		1	3	24	48	70	71	82	68	61	74	46	36	26	19	25
C74 Adrenal gland		3							1		2	1					
C76 Other and dill-defined sites		4		1										1	1		
C77 Lymph nodes		2	6	6	13	9	13	7	4	10	14	15	20	24	25	17	14
C80 Unknown primary site						2	2	5	9	12	11	25	25	29	27	25	19

Table 11: Cancer incidence by sub-site and histological type, 2007

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
<b>Lip, oral cavity &amp; pharynx (C00-C06, C09-C14)</b>							
800	Neoplasms, NOS	173	12.2	65	16.3	238	13.1
801-804	Epithelial neoplasms, NOS	13	0.9	4	1.0	17	0.9
805-808	Squamous cell neoplasms	1200	84.8	311	78.1	1508	83.3
814-838	Adenomas and adenocarcinomas	12	0.8	6	1.5	18	1.0
843	Mucoepidermoid neoplasms	4	0.3	3	0.8	7	0.4
872-879	Nevi and melanomas	0	0.0	1	0.3	1	0.1
880	Soft tissue tumours and sarcomas, NOS	0	0.0	2	0.5	2	0.1
881-883	Fibromatous neoplasms	1	0.1	0	0.0	1	0.1
912-916	Blood vessel tumours	1	0.1	1	0.3	2	0.1
959	Malignant lymphomas, NOS or diffuse	9	0.6	5	1.3	14	0.8
965-966	Hodgkin lymphoma	1	0.1	0	0.0	1	0.1
967-969	Mature B-cell lymphomas	1	0.1	0	0.0	1	0.1
	<b>Total</b>	<b>1415</b>	<b>100.0</b>	<b>398</b>	<b>100.0</b>	<b>1813</b>	<b>100.0</b>
<b>Parotid, other and unspecified major salivary glands (C07-C08)</b>							
800	Neoplasms, NOS	4	11.4	4	13.3	8	12.3
801-804	Epithelial neoplasms, NOS	4	11.4	0	0.0	4	6.2
805-808	Squamous cell neoplasms	5	14.3	0	0.0	5	7.7
814-838	Adenomas and adenocarcinomas	9	25.7	6	20.0	15	23.1
843	Mucoepidermoid neoplasms	10	28.6	15	50.0	25	38.5
850-854	Ductal and lobular neoplasms	2	5.7	1	3.3	3	4.6
855	Acinar cell neoplasms	1	2.9	1	3.3	2	3.1
893-899	Complex mixed and stromal neoplasms	0	0.0	1	3.3	1	1.5
959	Malignant lymphomas, NOS or diffuse	0	0.0	2	6.7	2	3.1
	<b>Total</b>	<b>35</b>	<b>100.0</b>	<b>30</b>	<b>100.0</b>	<b>65</b>	<b>100.0</b>
<b>Digestive organs (C15-C26)</b>							
800	Neoplasms, NOS	240	17.5	200	17.5	440	17.5
801-804	Epithelial neoplasms, NOS	10	0.7	10	0.9	20	0.8
805-808	Squamous cell neoplasms	363	26.4	423	37.1	786	31.2
812-813	Transitional cell papillomas and carcinomas	0	0.0	2	0.2	2	0.1
814-838	Adenomas and adenocarcinomas	679	49.4	448	39.3	1127	44.8
844-849	Cystic, mucinous and serous neoplasms	52	3.8	38	3.3	90	3.6
850-854	Ductal and lobular neoplasms	1	0.1	1	0.1	2	0.1
856-857	Complex epithelial neoplasms	3	0.2	0	0.0	3	0.1
872-879	Nevi and melanomas	2	0.1	1	0.1	3	0.1
880	Soft tissue tumours and sarcomas, NOS	1	0.1	2	0.2	3	0.1
889-892	Myomatous neoplasms	2	0.1	1	0.1	3	0.1
893-899	Complex mixed and stromal neoplasms	11	0.8	9	0.8	20	0.8
935-937	Miscellaneous tumours	1	0.1	0	0.0	1	0.0
947	Primitive neuroectodermal tumour, NOS	0	0.0	1	0.1	1	0.0
959	Malignant lymphomas, NOS or diffuse	1	0.1	4	0.4	5	0.2
967-969	Mature B-cell lymphomas	8	0.6	1	0.1	9	0.4
973	Plasma cell tumours	1	0.1	0	0.0	1	0.0
	<b>Total</b>	<b>1375</b>	<b>100.0</b>	<b>1141</b>	<b>100.0</b>	<b>2516</b>	<b>100.0</b>
<b>Respiratory &amp; intrathoracic organs (C30-C39)</b>							
800	Neoplasms, NOS	226	19.9	67	26.8	293	21.2
801-804	Epithelial neoplasms, NOS	183	16.2	29	11.6	212	15.3
805-808	Squamous cell neoplasms	516	45.6	60	24.0	575	41.7
812-813	Transitional cell papillomas and carcinomas	1	0.1	0	0.0	1	0.1
814-838	Adenomas and adenocarcinomas	173	15.3	77	30.8	250	18.1

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
844-849	Cystic, mucinous and serous neoplasms	2	0.2	1	0.4	3	0.2
856-857	Complex epithelial neoplasms	1	0.1	0	0.0	1	0.1
858	Thymic epithelial neoplasms	5	0.4	4	1.6	9	0.7
872-879	Nevi and melanomas	1	0.1	0	0.0	1	0.1
880	Soft tissue tumours and sarcomas, NOS	2	0.2	2	0.8	4	0.3
881-883	Fibromatous neoplasms	1	0.1	0	0.0	1	0.1
905	Mesothelial neoplasms	2	0.2	1	0.4	3	0.2
906-909	Germ cell neoplasms	8	0.7	1	0.4	9	0.7
912-916	Blood vessel tumours	2	0.2	0	0.0	2	0.1
947	Primitive neuroectodermal tumour, NOS	0	0.0	1	0.4	1	0.1
949-952	Neuroepitheliomatous neoplasms	3	0.3	2	0.8	5	0.4
959	Malignant lymphomas, NOS or diffuse	3	0.3	4	1.6	7	0.5
965-966	Hodgkin lymphoma	1	0.1	0	0.0	1	0.1
970-971	Mature T-cell and NK-cell lymphomas	0	0.0	1	0.4	1	0.1
973	Plasma cell tumours	3	0.3	0	0.0	3	0.2
<b>Total</b>		<b>1133</b>	<b>100.0</b>	<b>250</b>	<b>100.0</b>	<b>1383</b>	<b>100.0</b>
<b>Bones, joints and articular cartilage (C40- C41)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
800	Neoplasms, NOS	1	2.2	1	1.7	2	1.9
918-924	Osseous and chondromatous neoplasms	22	47.8	36	60.0	58	54.7
925	Giant cell tumours	6	13.0	2	3.3	8	7.5
926	Miscellaneous bone tumours	13	28.3	14	23.3	27	25.5
959	Malignant lymphomas, NOS or diffuse	0	0.0	1	1.7	1	0.9
973	Plasma cell tumours	4	8.7	6	10.0	10	9.4
<b>Total</b>		<b>46</b>	<b>100.0</b>	<b>60</b>	<b>100.0</b>	<b>106</b>	<b>100.0</b>
<b>Hematopoietic and reticuloendothelial systems (C42)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
959	Malignant lymphomas, NOS or diffuse	15	2.8	12	2.6	27	2.7
965-966	Hodgkin lymphoma	1	0.2	0	0.0	1	0.1
967-969	Mature B-cell lymphomas	1	0.2	1	0.2	2	0.2
972	Precursor cell lymphoblastic lymphoma	2	0.4	0	0.0	2	0.2
973	Plasma cell tumours	143	26.8	123	26.7	266	26.8
980	Leukaemias, NOS	6	1.1	3	0.7	9	0.9
982-983	Lymphoid leukemias	158	29.6	99	21.5	257	25.9
984-993	Myeloid leukemias	162	30.3	168	36.5	330	33.2
994	Other leukemias	6	1.1	4	0.9	10	1.0
995-996	Chronic myeloproliferative disorders	13	2.4	8	1.7	21	2.1
998	Myelodysplastic syndromes	27	5.1	42	9.1	69	6.9
<b>Total</b>		<b>534</b>	<b>100.0</b>	<b>460</b>	<b>100.0</b>	<b>994</b>	<b>100.0</b>
<b>Skin (C44)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
800	Neoplasms, NOS	2	1.7	3	3.5	5	2.5
801-804	Epithelial neoplasms, NOS	0	0.0	2	2.3	2	1.0
805-808	Squamous cell neoplasms	69	60.0	33	38.4	102	50.7
809-811	Basal cell neoplasms	14	12.2	18	20.9	32	15.9
814-838	Adenomas and adenocarcinomas	1	0.9	0	0.0	1	0.5
839-842	Adnexal and skin appendage neoplasms	1	0.9	2	2.3	3	1.5
872-879	Nevi and melanomas	21	18.3	16	18.6	37	18.4
881-883	Fibromatous neoplasms	1	0.9	4	4.7	5	2.5
959	Malignant lymphomas, NOS or diffuse	3	2.6	3	3.5	6	3.0
967-969	Mature B-cell lymphomas	1	0.9	0	0.0	1	0.5
970-971	Mature T-cell and NK-cell lymphomas	2	1.7	2	2.3	4	2.0
975	Neoplasms of histiocytes and accessory lymphoid cells	0	0.0	3	3.5	3	1.5
<b>Total</b>		<b>115</b>	<b>100.0</b>	<b>86</b>	<b>100.0</b>	<b>201</b>	<b>100.0</b>

Cancer Incidence Data - 2007

Site and histology		Male		Female		Total	
Peripheral nerves and autonomic nervous system (C47)		No	%	No	%	No	%
936	Peripheral neuroectodermal tumour	5	29.4	2	13.3	7	21.9
949-952	Neuroepitheliomatous neoplasms	4	23.5	5	33.3	9	28.1
954-957	Nerve sheath tumours	8	47.1	8	53.3	16	50.0
	<b>Total</b>	<b>17</b>	<b>100.0</b>	<b>15</b>	<b>100.0</b>	<b>32</b>	<b>100.0</b>
Retroperitoneum and peritoneum (C48)		No	%	No	%	No	%
800	Neoplasms, NOS	1	7.7	1	7.7	2	7.7
814-838	Adenomas and adenocarcinomas	0	0.0	1	7.7	1	3.8
880	Soft tissue tumours and sarcomas, NOS	2	15.4	4	30.8	6	23.1
885-888	Lipomatous neoplasms	4	30.8	2	15.4	6	23.1
889-892	Myomatous neoplasms	2	15.4	2	15.4	4	15.4
906-909	Germ cell neoplasms	2	15.4	1	7.7	3	11.5
912-916	Blood vessel tumours	1	7.7	0	0.0	1	3.8
935-937	Miscellaneous tumours	0	0.0	1	7.7	1	3.8
954-957	Nerve sheath tumours	0	0.0	1	7.7	1	3.8
965-966	Hodgkin lymphoma	1	7.7	0	0.0	1	3.8
	<b>Total</b>	<b>13</b>	<b>100.0</b>	<b>13</b>	<b>100.0</b>	<b>26</b>	<b>100.0</b>
Connective, subcutaneous and other soft tissues (C49)		No	%	No	%	No	%
880	Soft tissue tumours and sarcomas, NOS	26	47.3	31	49.2	57	48.3
881-883	Fibromatous neoplasms	5	9.1	5	7.9	10	8.5
885-888	Lipomatous neoplasms	7	12.7	6	9.5	13	11.0
889-892	Myomatous neoplasms	11	20.0	9	14.3	20	16.9
904	Synovial-like neoplasms	5	9.1	10	15.9	15	12.7
912-916	Blood vessel tumours	0	0.0	2	3.2	2	1.7
925	Giant cell tumours	1	1.8	0	0.0	1	0.8
	<b>Total</b>	<b>55</b>	<b>100.0</b>	<b>63</b>	<b>100.0</b>	<b>118</b>	<b>100.0</b>
Breast (C50)		No	%	No	%	No	%
800	Neoplasms, NOS	11	22.0	273	14.3	284	14.5
801-804	Epithelial neoplasms, NOS	0	0.0	5	0.3	5	0.3
805-808	Squamous cell neoplasms	0	0.0	15	0.8	15	0.8
814-838	Adenomas and adenocarcinomas	2	4.0	12	0.6	14	0.7
844-849	Cystic, mucinous and serous neoplasms	2	4.0	29	1.5	31	1.6
850-854	Ductal and lobular neoplasms	32	64.0	1557	81.3	1589	80.9
856-857	Complex epithelial neoplasms	1	2.0	4	0.2	5	0.3
880	Soft tissue tumours and sarcomas, NOS	1	2.0	3	0.2	4	0.2
881-883	Fibromatous neoplasms	0	0.0	1	0.1	1	0.1
893-899	Complex mixed and stromal neoplasms	0	0.0	3	0.2	3	0.2
900-903	Fibroepithelial neoplasms	1	2.0	10	0.5	11	0.6
959	Malignant lymphomas, NOS or diffuse	0	0.0	2	0.1	2	0.1
	<b>Total</b>	<b>50</b>	<b>100.0</b>	<b>1914</b>	<b>100.0</b>	<b>1964</b>	<b>100.0</b>
Female genital organs (C51- C58)		No	%	No	%	No	%
800	Neoplasms, NOS			217	13.7	217	13.7
801-804	Epithelial neoplasms, NOS			21	1.3	21	1.3
805-808	Squamous cell neoplasms			617	39.0	617	39.0
809-811	Basal cell neoplasms			1	0.1	1	0.1
814-838	Adenomas and adenocarcinomas			372	23.5	372	23.5
844-849	Cystic, mucinous and serous neoplasms			229	14.5	229	14.5
856-857	Complex epithelial neoplasms			7	0.4	7	0.4
859-867	Specialised gonadal neoplasms			13	0.8	13	0.8
872-879	Nevi and melanomas			1	0.1	1	0.1
880	Soft tissue tumours and sarcomas, NOS			3	0.2	3	0.2
889-892	Myomatous neoplasms			18	1.1	18	1.1

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
893-899	Complex mixed and stromal neoplasms			31	2.0	31	2.0
900-903	Fibroepithelial neoplasms			3	0.2	3	0.2
905	Mesothelial neoplasms			1	0.1	1	0.1
906-909	Germ cell neoplasms			36	2.3	36	2.3
910	Trophoblastic neoplasms			11	0.7	11	0.7
	<b>Total</b>			<b>1581</b>	<b>100.0</b>	<b>1581</b>	<b>100.0</b>
<b>Male genital organs (C60 -C63)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
800	Neoplasms, NOS	126	30.8			126	30.8
801-804	Epithelial neoplasms, NOS	3	0.7			3	0.7
805-808	Squamous cell neoplasms	49	12.0			49	12.0
812-813	Transitional cell papillomas and carcinomas	3	0.7			3	0.7
814-838	Adenomas and adenocarcinomas	173	42.3			173	42.3
844-849	Cystic, mucinous and serous neoplasms	1	0.2			1	0.2
855	Acinar cell neoplasms	5	1.2			5	1.2
889-892	Myomatous neoplasms	3	0.7			3	0.7
906-909	Germ cell neoplasms	40	9.8			40	9.8
947	Primitive neuroectodermal tumour, NOS	1	0.2			1	0.2
959	Malignant lymphomas, NOS or diffuse	5	1.2			5	1.2
	<b>Total</b>	<b>409</b>	<b>100.0</b>			<b>409</b>	<b>100.0</b>
<b>Urinary tract (C64- C68)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
800	Neoplasms, NOS	17	8.9	9	11.4	26	9.7
801-804	Epithelial neoplasms, NOS	3	1.6	0	0.0	3	1.1
805-808	Squamous cell neoplasms	12	6.3	4	5.1	16	5.9
812-813	Transitional cell papillomas and carcinomas	92	48.4	26	32.9	118	43.9
814-838	Adenomas and adenocarcinomas	56	29.5	27	34.2	83	30.9
856-857	Complex epithelial neoplasms	0	0.0	1	1.3	1	0.4
889-892	Myomatous neoplasms	1	0.5	1	1.3	2	0.7
893-899	Complex mixed and stromal neoplasms	9	4.7	7	8.9	16	5.9
949-952	Neuroepitheliomatous neoplasms	0	0.0	2	2.5	2	0.7
954-957	Nerve sheath tumours	0	0.0	1	1.3	1	0.4
959	Malignant lymphomas, NOS or diffuse	0	0.0	1	1.3	1	0.4
	<b>Total</b>	<b>190</b>	<b>100.0</b>	<b>79</b>	<b>100.0</b>	<b>269</b>	<b>100.0</b>
<b>Eye and adnexa (C69)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
801-804	Epithelial neoplasms, NOS	0	0.0	1	4.0	1	2.0
805-808	Squamous cell neoplasms	2	8.0	3	12.0	5	10.0
814-838	Adenomas and adenocarcinomas	1	4.0	0	0.0	1	2.0
872-879	Nevi and melanomas	1	4.0	2	8.0	3	6.0
880	Soft tissue tumours and sarcomas, NOS	0	0.0	1	4.0	1	2.0
912-916	Blood vessel tumours	0	0.0	1	4.0	1	2.0
949-952	Neuroepitheliomatous neoplasms	16	64.0	10	40.0	26	52.0
959	Malignant lymphomas, NOS or diffuse	5	20.0	5	20.0	10	20.0
970-971	Mature T-cell and NK-cell lymphomas	0	0.0	1	4.0	1	2.0
993	Myeloid sarcoma	0	0.0	1	4.0	1	2.0
	<b>Total</b>	<b>25</b>	<b>100.0</b>	<b>25</b>	<b>100.0</b>	<b>50</b>	<b>100.0</b>
<b>Brain and other parts of central nervous system (C70- C72)</b>		<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>	<b>No</b>	<b>%</b>
800	Neoplasms, NOS	4	2.4	2	1.9	6	2.2
880	Soft tissue tumours and sarcomas, NOS	0	0.0	1	1.0	1	0.4
906-909	Germ cell neoplasms	1	0.6	0	0.0	1	0.4
912-916	Blood vessel tumours	0	0.0	1	1.0	1	0.4
938-948	Gliomas	157	92.4	93	89.4	250	91.2
949-952	Neuroepitheliomatous neoplasms	2	1.2	0	0.0	2	0.7

Cancer Incidence Data - 2007

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
953	Meningiomas	2	1.2	1	1.0	3	1.1
954-957	Nerve sheath tumours	0	0.0	2	1.9	2	0.7
959	Malignant lymphomas, NOS or diffuse	4	2.4	3	2.9	7	2.6
965-966	Hodgkin lymphoma	0	0.0	1	1.0	1	0.4
<b>Total</b>		<b>170</b>	<b>100.0</b>	<b>104</b>	<b>100.0</b>	<b>274</b>	<b>100.0</b>
Thyroid and other endocrine glands (C73- C75)		No	%	No	%	No	%
800	Neoplasms, NOS	13	9.6	25	3.8	38	4.8
801-804	Epithelial neoplasms, NOS	8	5.9	23	3.5	31	3.9
805-808	Squamous cell neoplasms	1	54.8	0	0.0	1	0.1
814-838	Adenomas and adenocarcinomas	103	76.3	589	88.9	692	86.7
851	Medullary carcinoma, NOS	3	2.2	13	2.0	16	2.0
868-871	Paragangliomas and glomus tumours	0	0.0	2	0.3	2	0.3
880	Soft tissue tumours and sarcomas, NOS	1	0.7	0	0.0	1	0.1
935-937	Miscellaneous tumours	1	0.7	0	0.0	1	0.1
949-952	Neuroepitheliomatous neoplasms	3	2.2	2	0.3	5	0.6
959	Malignant lymphomas, NOS or diffuse	2	1.5	8	1.2	10	1.3
967-969	Mature B-cell lymphomas	0	0.0	1	0.2	1	0.1
<b>Total</b>		<b>135</b>	<b>100.0</b>	<b>663</b>	<b>100.0</b>	<b>798</b>	<b>100.0</b>
Other and ill-defined sites (C76)		No	%	No	%	No	%
800	Neoplasms, NOS	3	23.1	2	28.6	5	25.0
805-808	Squamous cell neoplasms	3	23.1	0	0.0	3	15.0
814-838	Adenomas and adenocarcinomas	2	15.4	0	0.0	2	10.0
889-892	Myomatous neoplasms	1	7.7	0	0.0	1	5.0
905	Mesothelial neoplasms	1	7.7	0	0.0	1	5.0
906-909	Germ cell neoplasms	3	23.1	4	57.1	7	35.0
949-952	Neuroepitheliomatous neoplasms	0	0.0	1	14.3	1	5.0
<b>Total</b>		<b>13</b>	<b>100.0</b>	<b>7</b>	<b>100.0</b>	<b>20</b>	<b>100.0</b>
Lymph nodes (C77)		No	%	No	%	No	%
959	Malignant lymphomas, NOS or diffuse	195	65.0	131	65.8	326	65.3
965-966	Hodgkin lymphoma	76	25.2	46	23.0	122	24.4
967-969	Mature B-cell lymphomas	19	6.3	18	9.0	37	7.4
970-971	Mature T-cell and NK-cell lymphomas	2	0.7	2	1.0	4	0.8
972	Precursor cell lymphoblastic lymphoma	5	1.7	2	1.0	7	1.4
973	Plasma cell tumours	1	0.3	0	0.0	1	0.2
975	Neoplasms of histiocytes and accessory lymphoid cells	2	0.7	0	0.0	2	0.4
<b>Total</b>		<b>300</b>	<b>100.0</b>	<b>199</b>	<b>100.0</b>	<b>499</b>	<b>100.0</b>
Unknown primary site (C80)		No	%	No	%	No	%
800	Neoplasms, NOS	80	24.5	57	29.4	137	26.5
801-804	Epithelial neoplasms, NOS	21	6.4	16	8.4	37	7.2
805-808	Squamous cell neoplasms	112	34.4	28	14.7	140	27.1
814-838	Adenomas and adenocarcinomas	104	31.9	84	44.0	188	36.4
844-849	Cystic, mucinous and serous neoplasms	3	0.9	2	1.0	5	1.0
872-879	Nevi and melanomas	4	1.2	2	1.0	6	1.2
880	Soft tissue tumours and sarcomas, NOS	2	0.6	0	0.0	2	0.4
906-909	Germ cell neoplasms	0	0.0	1	0.5	1	0.2
912-916	Blood vessel tumours	0	0.0	1	0.5	1	0.2
<b>Total</b>		<b>326</b>	<b>100.0</b>	<b>191</b>	<b>100.0</b>	<b>517</b>	<b>100.0</b>

**Table 12: Lip, oral cavity and pharynx  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	1415	22.3	16.0	1.91
Female	398	5.5	4.0	0.49
Total	1813	13.3	9.6	1.17

ASR: Age standardized rate per 100,000 world population


Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	2	2	4
C00.1 External lower lip	10	5	15
C00.3 Mucosa of upper lip	2	0	2
C00.4 Mucosa of lower lip	5	0	5
C00.6 Commissure of lip	7	1	8
C00.9 Lip, NOS	6	0	6
C01.9 Base of tongue, NOS	119	13	132
C02.0 Dorsal surface of tongue, NOS	15	6	21
C02.1 Border of tongue	1	0	1
C02.9 Tongue, NOS	216	51	267
C03.0 Upper gum	23	12	35
C03.1 Lower gum	43	24	67
C03.9 Gum, NOS	11	4	15
C04.9 Floor of mouth, NOS	84	11	95
C05.0 Hard palate	17	4	21
C05.1 Soft palate, NOS	44	4	48
C05.2 Uvula	2	1	3
C05.9 Palate, NOS	25	11	36
C06.0 Cheek mucosa	300	125	425
C06.1 Vestibule of mouth	1	1	2
C06.2 Retromolar area	28	8	36
C06.8 Overlapping lesion of other and unspecified parts of mouth	1	0	1
C06.9 Mouth, NOS	30	12	42
C09.1 Tonsillar pillar	5	0	5
C09.9 Tonsil, NOS	123	11	134
C10.0 Vallecule	30	4	34
C10.3 Posterior wall of oropharynx	1	0	1
C10.9 Oropharynx, NOS	25	8	33
C11.1 Posterior wall of nasopharynx	0	1	1
C11.9 Nasopharynx, NOS	43	7	50
C12.9 Pyriform sinus	134	25	159
C13.0 Postcricoid region	26	28	54
C13.9 Hypopharynx NOS	5	0	5
C14.0 Pharynx, NOS	31	18	49
C14.8 Overlapping lesion of lip, oral cavity, pharynx	0	1	1
<b>Total</b>	<b>1415</b>	<b>398</b>	<b>1813</b>



Cancer Incidence Data - 2007

ICD O code and histology		Male	Female	Total
800	Neoplasms, NOS	173	65	238
801-804	Epithelial neoplasms, NOS	13	4	17
805-808	Squamous cell neoplasms	1200	311	1511
814-838	Adenomas and adenocarcinomas	12	6	18
843	Mucoepidermoid neoplasms	4	3	7
872-879	Nevi and melanomas	0	1	1
880	Soft tissue tumours and sarcomas, NOS	0	2	2
881-883	Fibromatous neoplasms	1	0	1
912-916	Blood vessel tumours	1	1	2
959	Malignant lymphomas, NOS or diffuse	9	5	14
965-966	Hodgkin lymphoma	1	0	1
967-969	Mature B-cell lymphomas	1	0	1
<b>Total</b>		<b>1415</b>	<b>398</b>	<b>1813</b>



**Table 13: Lip and anterior part of oral cavity  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	801	12.6	8.9	1.08
Female	266	3.7	2.7	0.34
Total	1067	7.8	5.7	0.69

ASR: Age standardized rate per 100,000 world population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	2	2	4
C00.1 External lower lip	10	5	15
C00.3 Mucosa of upper lip	2	0	2
C00.4 Mucosa of lower lip	5	0	5
C00.6 Commissure of lip	7	1	8
C00.9 Lip, NOS	6	0	6
C02.0 Dorsal surface of tongue, NOS	15	6	21
C02.1 Border of tongue	1	0	1
C02.9 Tongue, NOS	216	51	267
C03.0 Upper gum	23	12	35
C03.1 Lower gum	43	24	67
C03.9 Gum, NOS	11	4	15
C04.9 Floor of mouth, NOS	84	11	95
C05.0 Hard palate	17	4	21
C06.0 Cheek mucosa	300	125	425
C06.1 Vestibule of mouth	1	1	2
C06.2 Retromolar area	28	8	36
C06.9 Mouth, NOS	30	12	42
<b>Total</b>	<b>801</b>	<b>266</b>	<b>1067</b>

ICD O code and histology	Male	Female	Total
800 Neoplasm, malignant	100	42	142
801-804 Epithelial neoplasms, NOS	3	1	4
805-808 Squamous cell neoplasms	689	215	904
814-838 Adenomas and adenocarcinomas	5	3	8
843 Mucoepidermoid neoplasms	1	1	2
880 Soft tissue tumours and sarcomas, NOS	0	1	1
881-883 Fibromatous neoplasms	1	0	1
912-916 Blood vessel tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	2	2	4
<b>Total</b>	<b>801</b>	<b>266</b>	<b>1067</b>

**Table 14: Posterior part of oral cavity and pharynx****Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	614	9.7	6.8	0.83
Female	132	1.8	1.3	0.16
Total	746	5.5	4.0	0.48

ASR: Age standardized rate per 100,000 world population

ICD O code and site	Male	Female	Total
C01.9 Base of tongue, NOS	119	13	132
C05.1 Soft palate, NOS	44	4	48
C05.2 Uvula	2	1	3
C05.9 Palate, NOS	25	11	36
C06.8 Overlapping lesion of other and unspecified parts of mouth	1	0	1
C09.1 Tonsillar pillar	5	0	5
C09.9 Tonsil, NOS	123	11	134
C10.0 Vallecule	30	4	34
C10.3 Posterior wall of oropharynx	1	0	1
C10.9 Oropharynx, NOS	25	8	33
C11.1 Posterior wall of nasopharynx	0	1	1
C11.9 Nasopharynx, NOS	43	7	50
C12.9 Pyriform sinus	134	25	159
C13.0 Postcricoid region	26	28	54
C13.9 Hypopharynx NOS	5	0	5
C14.0 Pharynx, NOS	31	18	49
C14.8 Overlapping lesion of lip, oral cavity, pharynx	0	1	1
<b>Total</b>	<b>614</b>	<b>132</b>	<b>746</b>

ICD O code and histology	Male	Female	Total
800 Neoplasm, malignant	73	23	96
801-804 Epithelial neoplasms, NOS	10	3	13
805-808 Squamous cell neoplasms	511	96	607
814-838 Adenomas and adenocarcinomas	7	3	10
843 Mucoepidermoid neoplasms	3	2	5
872-879 Nevi and melanomas	0	1	1
880 Soft tissue tumours and sarcomas, NOS	0	1	1
912-916 Blood vessel tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	8	3	11
967-969 Mature B-cell lymphomas	1	0	1
<b>Total</b>	<b>614</b>	<b>132</b>	<b>746</b>


**Table 15: Trachea, bronchus and lungs  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	723	11.4	8.3	1.11
Female	178	2.4	1.8	0.23
Total	901	6.6	4.9	0.65

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C33.9 Trachea	1		1
C34.0 Main bronchus	7	0	7
C34.1 Upper lobe, lung	28	2	30
C34.2 Middle lobe, lung	6	1	7
C34.3 Lower lobe, lung	1	1	2
C34.9 Lung, NOS	680	174	854
<b>Total</b>	<b>723</b>	<b>178</b>	<b>901</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	184	54	237
801-804 Epithelial neoplasms, NOS	176	28	204
805-808 Squamous cell neoplasms	190	23	213
814-838 Adenomas and adenocarcinomas	168	72	240
844-849 Cystic, mucinous and serous neoplasms	2	1	3
856-857 Complex epithelial neoplasms	1	0	1
906-909 Germ cell neoplasms	1	0	1
973 Plasma cell tumours	1	0	1
<b>Total</b>	<b>723</b>	<b>178</b>	<b>901</b>




**Table 16: Larynx**  
**Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	343	5.4	3.9	0.54
Female	29	0.4	0.3	0.03
Total	372	2.7	2.0	0.27

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C32.0 Glottis	165	8	173
C32.1 Supraglottis	100	11	111
C32.2 Subglottis	5	2	7
C32.3 Laryngeal cartilage	5	0	5
C32.9 Larynx, NOS	68	8	76
<b>Total</b>	<b>343</b>	<b>29</b>	<b>372</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	28	3	31
801-804 Epithelial neoplasms, NOS	4	1	5
805-808 Squamous cell neoplasms	309	25	334
880 Soft tissue tumours and sarcomas, NOS	1	0	1
881-883 Fibromatous neoplasms	1	0	1
<b>Total</b>	<b>343</b>	<b>29</b>	<b>372</b>




**Table 17: Oesophagus**  
**Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	530	8.3	5.9	0.76
Female	534	7.3	5.6	0.71
Total	1064	7.8	5.7	0.74

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C15.0 Cervical oesophagus	1	1	2
C15.1 Thoracic oesophagus	1	1	2
C15.3 Upper third of oesophagus	7	11	18
C15.4 Middle third of oesophagus	119	163	282
C15.5 Lower third of oesophagus	150	140	290
C15.9 Oesophagus, NOS	252	218	470
Total	530	534	1064

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	106	100	206
801-804 Epithelial neoplasms, NOS	6	6	12
805-808 Squamous cell neoplasms	346	404	750
814-838 Adenomas and adenocarcinomas	67	16	83
844-849 Cystic, mucinous and serous neoplasms	2	6	8
856-857 Complex epithelial neoplasms	2	0	2
889-892 Myomatous neoplasms	1	0	1
959 Malignant lymphomas, NOS or diffuse	0	2	2
<b>Total</b>	<b>530</b>	<b>534</b>	<b>1064</b>




**Table 18: Stomach  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	224	3.5	2.5	0.32
Female	60	0.8	0.6	0.76
Total	284	2.1	1.5	0.19

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C16.0 Cardia, NOS	41	11	52
C16.1 Fundus of stomach	0	1	1
C16.3 Gastric antrum	3	3	6
C16.4 Pylorus	3	4	7
C16.6 Greater curvature of stomach, NOS	1	0	1
C16.9 Stomach, NOS	176	41	217
<b>Total</b>	<b>224</b>	<b>60</b>	<b>284</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	43	14	57
801-804 Epithelial neoplasms, NOS	3	1	4
805-808 Squamous cell neoplasms	8	4	12
814-838 Adenomas and adenocarcinomas	142	33	175
844-849 Cystic, mucinous and serous neoplasms	17	3	20
856-857 Complex epithelial neoplasms	1	0	1
880 Soft tissue tumours and sarcomas, NOS	1	1	2
893-899 Complex mixed and stromal neoplasms	6	3	9
947 Primitive neuroectodermal tumour	0	1	1
967-969 Mature B-cell lymphomas	3	0	3
<b>Total</b>	<b>224</b>	<b>60</b>	<b>284</b>




**Table 19: Colon and rectum  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	409	6.4	4.5	0.52
Female	405	5.6	4.1	0.49
Total	814	6.0	4.3	0.50

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	31	18	49
C18.1 Appendix	1	1	2
C18.2 Ascending colon	5	4	9
C18.3 Hepatic flexure of colon	4	3	7
C18.4 Transverse colon	7	3	10
C18.5 Splenic flexure of colon	4	1	5
C18.6 Descending colon	7	5	12
C18.7 Sigmoid colon	51	74	125
C18.9 Colon, NOS	85	68	153
C19.9 Rectosigmoid junction	18	23	41
C20.9 Rectum, NOS	196	205	401
<b>Total</b>	<b>409</b>	<b>405</b>	<b>814</b>

ICD O code and histology	Male	Female	Total
801 Neoplasms, NOS	46	45	91
801-804 Epithelial neoplasms, NOS	0	2	2
805-808 Squamous cell neoplasms	2	5	7
814-838 Adenomas and adenocarcinomas	323	320	643
844-849 Cystic, mucinous and serous neoplasms	33	28	61
872-879 Nevi and melanomas	1	1	2
880 Soft tissue tumours and sarcomas, NOS	0	1	1
889-892 Myomatous neoplasms	0	1	1
935-937 Miscellaneous tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
967-969 Mature B-cell lymphomas	3	1	4
<b>Total</b>	<b>409</b>	<b>405</b>	<b>814</b>






**Table 20: Colon  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	195	3.1	2.1	0.25
Female	177	2.4	1.8	0.22
Total	372	2.7	2.0	0.23

ASR: Age standardized rate per 100,000 world population

ICD O code and site	Male	Female	Total
C18.0 Cecum	31	18	49
C18.1 Appendix	1	1	2
C18.2 Ascending colon	5	4	9
C18.3 Hepatic flexure of colon	4	3	7
C18.4 Transverse colon	7	3	10
C18.5 Splenic flexure of colon	4	1	5
C18.6 Descending colon	7	5	12
C18.7 Sigmoid colon	51	74	125
C18.9 Colon, NOS	85	68	153
<b>Total</b>	<b>195</b>	<b>177</b>	<b>372</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	15	16	31
801-804 Epithelial neoplasms, NOS	0	1	1
805-808 Squamous cell neoplasms	0	2	2
814-838 Adenomas and adenocarcinomas	157	135	292
844-849 Cystic, mucinous and serous neoplasms	21	18	39
872-879 Nevi and melanomas	0	1	1
880 Soft tissue tumours and sarcomas, NOS	0	1	1
889-892 Myomatous neoplasms	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
967-969 Mature B-cell lymphomas	2	1	3
<b>Total</b>	<b>195</b>	<b>177</b>	<b>372</b>




**Table 21: Rectum, anal canal and anus  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	210	3.3	2.3	0.26
Female	220	3.0	2.2	0.25
Total	430	3.2	2.2	0.26

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C20.9 Rectum, NOS	196	205	401
C21.0 Anus, NOS	7	7	14
C21.1 Anal canal	3	6	9
C21.8 Overlapping lesion rectum, anal canal and anus	4	2	6
<b>Total</b>	<b>210</b>	<b>220</b>	<b>430</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	31	27	58
801-804 Epithelial neoplasms, NOS	0	1	1
805-808 Squamous cell neoplasms	7	11	18
812-813 Transitional cell papillomas and carcinomas	0	2	2
814-838 Adenomas and adenocarcinomas	157	169	326
844-849 Cystic, mucinous and serous neoplasms	11	10	21
872-879 Nevi and melanomas	2	0	2
935-937 Miscellaneous tumours	1	0	1
967-969 Mature B-cell lymphomas	1	0	1
<b>Total</b>	<b>210</b>	<b>220</b>	<b>430</b>




**Table 22: Breast  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	50	0.8	0.5	0.06
Female	1914	26.3	18.8	2.08
Total	1964	14.4	9.9	1.10

ASR: Age standardized rate per 100,000 world population  
 Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C50.0 Nipple	0	1	1
C50.6 Axillary tail of breast	0	1	1
C50.9 Breast, NOS	50	1912	1962
<b>Total</b>	<b>50</b>	<b>1914</b>	<b>1964</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	11	273	284
801-804 Epithelial neoplasms, NOS	0	5	5
805-808 Squamous cell neoplasms	0	15	15
814-838 Adenomas and adenocarcinomas	2	12	14
844-849 Cystic, mucinous and serous neoplasms	2	29	31
850-854 Ductal and lobular neoplasms	32	1557	1589
856-857 Complex epithelial neoplasms	1	4	5
880 Soft tissue tumours and sarcomas, NOS	1	3	4
881-883 Fibromatous neoplasms	0	1	1
893-899 Complex mixed and stromal neoplasms	0	3	3
900-903 Fibroepithelial neoplasms	1	10	11
959 Malignant lymphomas, NOS or diffuse	0	2	2
<b>Total</b>	<b>50</b>	<b>1914</b>	<b>1964</b>




**Table 23: Cervix uteri  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Female	732	10.1	7.4	0.87

ASR: Age standardized rate per 100,000 world population  
 Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C53.0 Endocervix	2
C53.8 Overlapping lesion of cervix uteri	1
C53.9 Cervix uteri	729
<b>Total</b>	<b>732</b>

ICD O code and histology	Female
800 Neoplasms, NOS	115
801-804 Epithelial neoplasms, NOS	11
805-808 Squamous cell neoplasms	561
814-838 Adenomas and adenocarcinomas	36
844-849 Cystic, mucinous and serous neoplasms	4
856-857 Complex epithelial neoplasms	4
889-892 Myomatous neoplasms	1
<b>Total</b>	<b>732</b>




**Table 24: Ovary  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Female	529	7.2	5.3	0.60

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C56.9 Ovary	529
<b>Total</b>	<b>529</b>

ICD O code and histology	Female
800 Neoplasms, NOS	87
801-804 Epithelial neoplasms, NOS	3
805-808 Squamous cell neoplasms	14
814-838 Adenomas and adenocarcinomas	140
844-849 Cystic, mucinous and serous neoplasms	222
859-867 Specialised gonadal neoplasms	13
880 Soft tissue tumours and sarcomas, NOS	1
889-892 Myomatous neoplasms	1
893-899 Complex mixed and stromal neoplasms	6
900-903 Fibroepithelial neoplasms	3
905 Mesothelial neoplasms	1
906-909 Germ cell neoplasms	36
910 Trophoblastic neoplasms	2
<b>Total</b>	<b>529</b>




**Table 25: Skin  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	115	1.8	1.3	0.14
Female	86	1.2	0.8	0.09
Total	201	1.5	1.0	0.12

ASR: Age standardized rate per 100,000 world population  
 Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C44.0 Skin of lip, NOS	3	1	4
C44.1 Eyelid	0	3	3
C44.2 External ear	6	7	13
C44.3 Skin, other & unspecified parts of face	12	10	22
C44.4 Skin of scalp and neck	12	11	23
C44.5 Skin of trunk	13	13	26
C44.6 Skin of upper limb and shoulder	4	7	11
C44.7 Skin of lower limb and hip	52	21	73
C44.9 Skin, NOS	13	13	26
<b>Total</b>	<b>115</b>	<b>86</b>	<b>201</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	2	3	5
801-804 Epithelial neoplasms, NOS	0	2	2
805-808 Squamous cell neoplasms	69	33	102
809-811 Basal cell neoplasms	14	18	32
814-838 Adenomas and adenocarcinomas	1	0	1
839-842 Adnexal and skin appendage neoplasms	1	2	3
872-879 Nevi and melanomas	21	16	37
881-883 Fibromatous neoplasms	1	4	5
959 Malignant lymphomas, NOS or diffuse	3	3	6
967-969 Mature B-cell lymphomas	1	0	1
970-971 Mature T- and NK cell lymphomas	2	2	4
975 Neoplasms of histiocytes and accessory lymphoid cells	0	3	3
<b>Total</b>	<b>115</b>	<b>86</b>	<b>201</b>




**Table 26: Brain  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	164	2.6	1.7	0.16
Female	97	1.3	1.0	0.08
Total	261	1.9	1.3	0.12

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C71.0 Cerebrum	13	5	18
C71.1 Frontal lobe	18	10	28
C71.1 Frontal lobe	14	3	17
C71.3 Parietal lobe	32	20	52
C71.4 Occipital lobe	7	8	15
C71.5 Ventricle, NOS	3	1	4
C71.6 Cerebellum, NOS	4	2	6
C71.7 Brain stem	10	4	14
C71.8 Overlapping lesion of brain	1	1	2
C71.9 Brain, NOS	62	43	105
<b>Total</b>	<b>164</b>	<b>97</b>	<b>261</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	4	2	6
880 Soft tissue tumours and sarcomas, NOS	0	1	1
906-909 Germ cell neoplasms	1	0	1
938-948 Gliomas	154	90	244
949-952 Neuroepitheliomatous neoplasms	1	0	1
954-957 Nerve sheath tumours	0	2	2
959 Malignant lymphomas, NOS or diffuse	4	2	6
<b>Total</b>	<b>164</b>	<b>97</b>	<b>261</b>




**Table 27: Thyroid gland  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	130	2.0	1.3	0.14
Female	656	9.0	6.1	0.56
Total	786	5.8	3.7	0.36

ASR: Age standardized rate per 100,000 world population  
 Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C73.9 Thyroid gland	130	656	786
<b>Total</b>	<b>130</b>	<b>656</b>	<b>786</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	13	24	37
801-804 Epithelial neoplasms, NOS	8	23	31
805-808 Squamous cell neoplasms	1	0	1
814-838 Adenomas and adenocarcinomas	102	587	689
851 Medullary carcinoma, NOS	3	13	16
880 Soft tissue tumours and sarcomas, NOS	1	0	1
959 Malignant lymphomas, NOS or diffuse	2	8	10
967-969 Mature B-cell lymphomas	0	1	1
<b>Total</b>	<b>130</b>	<b>656</b>	<b>786</b>






**Table 28: Urinary bladder  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	115	1.8	1.3	0.16
Female	36	0.5	0.4	0.05
Total	151	1.1	0.8	0.10

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C67.9 Urinary bladder, NOS	115	36	151
<b>Total</b>	<b>115</b>	<b>36</b>	<b>151</b>

ICD O code and histology	Male	Female	Total
800 Neoplasms, NOS	13	8	21
801-804 Epithelial neoplasms, NOS	2	0	2
805-808 Squamous cell neoplasms	10	2	12
812-813 Transitional cell papillomas and carcinomas	86	19	105
814-838 Adenomas and adenocarcinomas	3	3	6
856-857 Complex epithelial neoplasms	0	1	1
889-892 Myomatous neoplasms	1	1	2
954-957 Nerve sheath tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
<b>Total</b>	<b>115</b>	<b>36</b>	<b>151</b>




**Table 29: Hematopoietic and reticuloendothelial system  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	534	8.4	5.9	0.59
Female	460	6.3	4.8	0.49
Total	994	7.3	5.3	0.54

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C42.1 Bone marrow	533	460	993
C42.2 Spleen	1	0	1
<b>Total</b>	<b>534</b>	<b>460</b>	<b>994</b>

ICD O code and histology	Male	Female	Total
959 Malignant lymphomas, NOS or diffuse	15	12	27
965-966 Hodgkin lymphoma	1	0	1
967-969 Mature B-cell lymphomas	1	1	2
972 Precursor cell lymphoblastic lymphoma	2	0	2
973 Plasma cell tumours	143	123	266
980 Leukaemia, NOS	6	3	9
982-983 Lymphoid leukemias	158	99	257
984-993 Myeloid leukemias	162	168	330
994 Other leukemias	6	4	10
995-996 Chronic myeloproliferative disorders	13	8	21
998 Myelodysplastic syndromes	27	42	69
<b>Total</b>	<b>534</b>	<b>460</b>	<b>994</b>




**Table 30: Prostate gland  
Incidence data 2007**

Group	Number	Percentage	ASR	Cum. Rate
Male	305	4.8	3.6	0.47

ASR: Age standardized rate per 100,000 world population  
Cum. Rate- Cumulative Rate (0-74 years) per 100 population




ICD O code and site	Male
C61.9 Prostate gland	305
<b>Total</b>	<b>305</b>

ICD O code and histology	Male
800 Neoplasms, NOS	117
801-804 Epithelial neoplasms, NOS	3
805-808 Squamous cell neoplasms	1
812-813 Transitional cell papillomas and carcinomas	3
814-838 Adenomas and adenocarcinomas	173
844-849 Cystic, mucinous and serous neoplasms	1
855 Acinar cell neoplasms	5
889-892 Myomatous neoplasms	1
947 Primitive neuroectodermal tumour	1
<b>Total</b>	<b>305</b>



### Staging data of common cancers -2007

Figures 23, 24 and 25 give the staging information of the three main cancers in Sri Lanka. However staging information was available for 58.5% of cervical cancers, 42.8% of breast cancers and 18.4% of oral cancers. The percentages of different stages given are out of the cancers with staging information.



**Table 31: Basis of diagnosis of cancer patients- 2007**

Basis of diagnosis	Frequency	Percent
<b>Diagnosed Microscopically</b>		
Histology of primary	10,244	75.1
Histology of metastases	660	4.8
Cytology/Haematology	1594	11.7
<b>Subtotal</b>	<b>12,498</b>	<b>91.7</b>
<b>Diagnosed non microscopically</b>		
Clinical Investigation including US, X-rays etc.	465	3.4
Exploratory Surgery	25	0.2
Specific biochemical/immunological tests	72	0.5
Clinical only	128	0.9
<b>Subtotal</b>	<b>690</b>	<b>5.0</b>
<b>Unknown/ Not recorded</b>	<b>447</b>	<b>3.3</b>
<b>Total</b>	<b>13,635</b>	<b>100.0</b>





Table 32: Cancer treatment - 2007

Treatment	Number	Percentage
Surgery (S)	910	6.6
Radiotherapy (R )	1566	11.4
Chemotherapy (C )	2080	15.2
Hormone (H)	61	0.4
Other- Symptomatic treatment (O)	132	1.0
S+R	983	7.2
S+C	1139	8.3
S+H	334	2.4
S+O	75	0.5
R+C	1421	10.4
R+H	79	0.6
R+O	184	1.3
C+H	18	0.1
C+O	182	1.3
H+O	9	0.1
S+R+C	947	6.9
S+R+H	459	3.4
S+R+O	101	0.7
S+C+H	123	0.9
S+C+O	101	0.7
S+H+O	33	0.2
R+C+H	36	0.3
R+C+O	169	1.2
R+H+O	10	0.1
C+H+O	9	0.1
S+R+C+H	646	4.7
S+R+C+O	121	0.9
S+C+H+O	10	0.1
S+R+H+O	41	0.3
R+C+H+O	8	0.1
S+R+C+H+O	48	0.4
Treatment unknown	1650	12.1
Total	13,635	100.0

**Figure 28: Percentage of patients who received different types of treatment**









Table 33: Cancer Incidence by Geographical area- 2007

Province	District	Male		Female		Total	
		No.	%	No.	%	No.	%
Central	Not Known	188	3.0	239	3.3	427	3.1
	Kandy	624	9.8	759	10.4	1383	10.1
	Matale	159	2.5	183	2.5	342	2.5
Eastern	Nuwara Eliya	181	2.8	233	3.2	414	3.0
	Trincomalee	69	1.1	51	.7	120	.9
	Bataloa	87	1.4	69	.9	156	1.1
Northern	Ampara	122	1.9	101	1.4	223	1.6
	Vavuniya	43	.7	49	.7	92	.7
	Mullative	8	.1	21	.3	29	.2
North Central	Kilinochchi	27	.4	29	.4	56	.4
	Mannar	18	.3	10	.1	28	.2
	Jaffna	98	1.5	135	1.9	233	1.7
North Western	Anuradhapura	242	3.8	249	3.4	491	3.6
	Polonnaruwa	88	1.4	100	1.4	188	1.4
Sabaragamuwa	Kurunegala	544	8.6	463	6.4	1007	7.4
	Puttalam	178	2.8	202	2.8	380	2.8
Southern	Ratnapura	250	3.9	321	4.4	571	4.2
	Kegalle	319	5.0	289	4.0	608	4.5
Uva	Galle	446	7.0	484	6.6	930	6.8
	Matara	274	4.3	315	4.3	589	4.3
	Hambantota	124	2.0	166	2.3	290	2.1
Western	Monaragala	70	1.1	78	1.1	148	1.1
	Badulla	273	4.3	345	4.7	618	4.5
Total	Colombo	921	14.5	1267	17.4	2188	16.0
	Gampaha	687	10.8	768	10.6	1455	10.7
	Kalutara	316	5.0	353	4.8	669	4.9
Total		6356	100.0	7279	100.0	13635	100.0



Figure 29





Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population


### Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population

### Cancer Incidence by District -2007




No. Number of cases

CR: Crude Rate per 100,000 population

Figure 30


Male Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population


### Male Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population

### Male Cancer Incidence by District -2007




No. Number of cases

CR: Crude Rate per 100,000 population

Figure 31


Female Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population

### Female Cancer Incidence by District -2007




No. Number of cases

CR: Crude Rate per 100,000 population



### Female Cancer Incidence by District -2007



No. Number of cases

CR: Crude Rate per 100,000 population

## **List of References**

Cancer Registry, National Cancer Control Programme (2012), Sri Lanka Cancer Incidence Data; Sri Lanka 2006

Department of Census and Statistics (2012): Number of death by cause, age and sex (2001, 2002, 2003, 2004, 2005, 2006)

<http://www.statistics.gov.lk/PopHouSat/VitalStatistics/Tables>

Department of Census and Statistics; Estimated midyear population by age and sex, 2000-2006

<http://www.statistics.gov.lk/PopHouSat/Mid%20Year%20Population/midyearsex&age.pdf> [01 Dec 2011]

Doll, R., Payne, P., Waterhouse, J.A.H. eds (1966). *Cancer Incidence in Five Continents, Vol. I.* Union Internationale Contre le Cancer, Geneva.

Fritz, A. Percy, C. Jack, A. Shanmugaratnam, K. Sobin, L. Parkin, D.M. Whelan S. (ed) (2009) *International Classification of Diseases of Oncology, 3rd Edition* WHO, Geneva

Glossary of statistical terms; <http://www-dep.iarc.fr/NORDCAN/english/glossary.htm> [01 Dec 2011]

Indian Cancer Society, Parel, Mumbai, India (2009) *Cancer Incidence and Mortality in Greater Mumbai, 2005*

K.S.Chia, A. Seow, H.P. Lee, K. Shanmugaratnam; (2000) *Cancer Incidence in Singapore 1993-1997*; Singapore Cancer Registry

Medical Statistics Unit, Ministry of Health, Sri Lanka (2008) *Annual Health Statistics, Sri Lanka 2006*

National Cancer Centre, Ministry of Health and Welfare, Republic of Korea (2011) *Cancer Facts & Figures 2011*

Segi, M. (1960) *Cancer Mortality for Selected Sites in 24 Countries (1950–57)*. Department of Public Health, Tohoku University of Medicine, Sendai, Japan

## Appendix I- Statistical Terminology

### Population at risk

It is the part of a population which is susceptible to develop a specific cancer. It is defined on the basis of demographic data, such as place of residence, sex, age group, etc. Years of risk duration are counted in person-years

### Incidence

Incidence quantifies the number of new cases of disease that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

### Mortality

It is usually expressed as a rate. It is a measure of the number of deaths (in general due to a specific cause) in a specific population, per unit time. Mortality rate is typically expressed in units of deaths per 1000 individuals per year.

### Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. It is usually expressed as an annual rate per 100,000 persons at risk.

### Crude incidence rate

= Total number of cases in the year/ Total midyear population at risk

### Crude death rate

= Total number of deaths in the year/ Total midyear population at risk

### Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five-year age categories are used (highest group 75+).

### Age –specific incidence rate

= Number of cases in the five-year age group/ population at risk in the corresponding age group

### Age –specific death rate

= Number of deaths in the five-year age group/ population at risk in the corresponding age group

### ASR (age-standardised rate)

Standardised rates are statistically constructed summary rates that account for the difference between populations. An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardisation is necessary when comparing several populations that differ with respect to age because age has such a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. In this publication 'World Population' was taken as the standard population.

NATIONAL CANCER CONTROL PROGRAMME,  
NO. 555, PUBLIC HEALTH COMPLEX,  
ELVITIGALA MAWATHA, COLOMBO 05.